TABLE 1.
Patient Baseline Characteristics, Grouped by Adult-onset and Elderly-onset Disease
| Patient Characteristics at Cohort Entry | Adult-Onset IBD (N = 191) | Elderly-Onset IBD (N = 165) | P |
|---|---|---|---|
| Age at cohort entry, mean years (SD) | 67.2 (5.3) | 71.7 (7.9) | <0.01 |
| Age at diagnosis, mean years (SD) | 37.5 (14) | 68.6 (7.4) | <0.01 |
| Sex, male n (%) | 105 (55) | 83 (50.3) | 0.38 |
| Smoking, n (%) | <0.01 | ||
| Current | 12 (6.3) | 2 (1.2) | |
| Former | 77 (40.3) | 84 (51.2) | |
| Never | 102 (53.4) | 78 (47.6) | |
| Race/ethnicity, n (%) | 0.09 | ||
| African American | 4 (2.1) | 6 (3.8) | |
| Asian | 5 (2.7) | 11 (6.9) | |
| White | 166 (88.8) | 132 (82.5) | |
| Hispanic | 3 (1.6) | 7 (4.4) | |
| Other | 9 (4.8) | 4 (2.5) | |
| BMI, mean (SD) | 25.7 (5.2) | 25.9 (5.2) | 0.70 |
| Proportion obese, n (%) | 37 (19.4) | 27 (16.4) | 0.46 |
| Comorbidities, n (%) | |||
| Diabetes | 30 (15.7) | 22 (13.3) | 0.53 |
| Coronary artery disease | 19 (9.9) | 28 (17) | 0.051 |
| Congestive heart failure | 11 (5.8) | 7 (4.2) | 0.51 |
| Stroke/TIA or vascular disease | 12 (6.3) | 16 (9.7) | 0.23 |
| COPD | 5 (2.6) | 10 (6.1) | 0.11 |
| Hypertension | 93 (48.7) | 89 (53.9) | 0.32 |
| Hyperlipidemia | 65 (34) | 71 (43) | 0.08 |
| Chronic kidney disease | 25 (13.1) | 12 (7.3) | 0.07 |
| Type of IBD, n (%; n = 66) | |||
| CD | 108 (56.5) | 75 (45.5) | 0.04 |
| UC | 83 (43.5) | 90 (54.5) | |
| Disease extent: UC, n (%) | 66 | 82 | 0.94 |
| E1 | 5 (7.6) | 7 (8.5) | |
| E2 | 19 (28.8) | 25 (30.5) | |
| E3 | 42 (63.6) | 50 (61) | |
| Disease extent: CD, n (%) | 103 | 75 | <0.01 |
| L1 | 18 (17.5) | 24 (32) | |
| L2 | 16 (15.5) | 22 (29.3) | |
| L3 | 69 (67) | 29 (38.7) | |
| CD behavior: stricturing, n (%) | 65 (60.7) | 25 (33.3) | <0.01 |
| CD behavior: penetrating, n (%) | 39 (36.4) | 16 (21.3) | 0.03 |
| CD behavior: perianal, n (%) | 26 (13.8) | 11 (6.7) | 0.03 |
| Current IBD medications, n (%) | |||
| 5-ASA | 72 (37.7) | 81 (49.1) | 0.03 |
| Corticosteroids | 41 (21.5) | 52 (31.5) | 0.03 |
| Immunomodulators | 37 (19.4) | 18 (10.9) | 0.03 |
| Biologics | 39 (20.4) | 22 (13.3) | 0.07 |
| Prior IBD medications, n (%) | |||
| 5-ASA | 154 (81.1) | 115 (69.7) | 0.01 |
| Corticosteroids | 140 (73.7) | 93 (56.4) | <0.01 |
| Immunomodulators | 94 (49.5) | 40 (24.2) | <0.01 |
| Biologics | 73 (38.2) | 35 (21.2) | <0.01 |
| Prior serious infection, n (%) | 20 (10.5) | 25 (15.2) | 0.19 |
| Prior malignancy, n (%) | 45 (23.6) | 41 (24.8) | 0.78 |
| Type of malignancy, n (%) | 0.80 | ||
| Hematologic | 5 (11.40 | 6 (14.6) | |
| Melanoma | 6 (13.6) | 4 (9.8) | |
| Solid | 33 (75) | 31 (75.6) | |
| Current remission, n (%) | 142 (74.4) | 133 (80.5) | 0.51 |
| Prior GI surgery, n (%) | 99 (51.8) | 29 (17.6) | <0.01 |
| Prior hospitalization, n (%) | 149 (78) | 118 (71.5) | 0.16 |
Abbreviations: TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; 5-ASA, 5-aminosalicylates; GI, gastrointestinal